The vaccine landscape in 2025 is seeing significant changes. Scientists and pharmaceutical companies are rolling out updated COVID-19 vaccines, expanding vaccination schedules, and improving influenza protection.
Quoted from various sources and reported from pafikutaikab.org these breakthroughs could reshape how we protect populations, especially the elderly and those with underlying health risks.
New COVID-19 Vaccines and Strong Immune Responses
- Moderna has unveiled its next-generation COVID-19 vaccine, mNEXSPIKE, which shows a strong immune response in adults aged 65+ and in younger adults with risk conditions. The vaccine produces more than a 16-fold increase in neutralizing antibodies against the LP.8.1 variant, now more widespread globally.
- Pfizer and BioNTech also released data from their Phase 3 trial of an updated vaccine formula for the 2025-2026 season, specifically adapted to the LP.8.1 sublineage of SARS-CoV-2. In older adults and those with underlying health conditions, they report at least a 4-fold increase in neutralizing antibodies
These developments mark a step forward in vaccine precision, adapting to evolving virus variants and aiming to offer better protection to those most vulnerable.
See also: Health Insurance for Living Abroad: A Complete Guide for Expats
Influenza Vaccine Advances
Moderna’s experimental influenza vaccine, called mRNA-1010, has shown promising results. In a large late-stage trial involving adults aged 50 years and older, it demonstrated efficacy about 26.6% higher than currently licensed flu vaccines. Among participants aged 65+, the efficacy improvement was approximately 27.4%.
This advance may be particularly relevant for health systems preparing for the upcoming flu season, as flu and COVID-19 continue to co-circulate in many regions.
Protein-Based Vaccines for Those Unwilling or Unsuitable for mRNA
Novavax’s Nuvaxovid™ 2025-2026 Formula has been approved in the U.S. as a protein-based, non-mRNA COVID-19 vaccine option for older adults and individuals with certain risk factors. This offers an alternative for those who may prefer or need vaccines that do not use mRNA technology.
Challenges and Considerations
While vaccine progress is encouraging, several challenges remain:
- Eligibility Restrictions: Some of the new vaccines are authorized for limited populations, such as people 65+ or those with underlying conditions. Expanding eligibility will require careful safety monitoring and public health planning.
- Vaccine Hesitancy: Changes in vaccine guidelines and differing vaccine technologies can raise concerns among the public. Effective communication is essential.
- Supply and Logistics: Producing, distributing, and storing updated vaccines — especially in regions with limited cold chain infrastructure — remains a logistical hurdle.
What This Means for Indonesia and Global Public Health
For countries like Indonesia, the latest vaccine updates offer both opportunity and responsibility:
- Prioritizing vulnerable groups (elderly, immunocompromised) for updated COVID-19 and flu vaccinations could reduce severe cases and hospitalisation.
- Monitoring local variant trends to decide which vaccine formulations provide the best match.
- Strengthening vaccine infrastructure (cold storage, access, public education) to ensure equitable distribution and uptake.
2025 is proving to be a pivotal year for vaccine development. With updated COVID-19 vaccines, improved flu vaccine efficacy, and non-mRNA options becoming available, public health strategies are adapting to a changing viral environment. The success of these breakthroughs will depend heavily on effective public communication, broad access, and proper implementation. Countries that act swiftly and strategically stand to gain the most in reducing disease burden in the coming years.
